OncoMatch/Clinical Trials/NCT07432633
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
Is NCT07432633 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1/2 trial studies [18F]FPyQCP for colorectal cancer.
Treatment: [18F]FPyQCP — This is a multi-center, open-label, single-arm, Phase 1/2 study designed to evaluate the safety, radiation dosimetry, and preliminary diagnostic performance of \[18F\]FPyQCP in detecting colorectal cancer (CRC), gastric cancer (GC), pancreatic ductal adenocarcinoma (PDAC), invasive lobular breast cancer (ILC), and epithelial ovarian cancer (EOC).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Colorectal Cancer
Ovarian Cancer
Gastric Cancer
Breast Carcinoma
Pancreatic Cancer
Disease stage
Required: Stage I, II, III
Excluded: Stage IV (EXCEPT OLIGOMETASTATIC DISEASE [5 OR FEWER KNOWN METASTASES])
stage I-III (see Appendix 3) CRC, GC, PDAC, ILC, or EOC (stage IV disease is allowed in the setting of oligometastatic disease [5 or fewer known metastases])
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Demographics
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- University of Texas Southwestern Medical Center · Dallas, Texas
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT07432633 currently recruiting?
Yes, this trial is currently recruiting patients.
What disease stage is eligible?
Stage I or II or III is required.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages